Options XII for the Control of Influenza
Brisbane, Australia September 30, 2024
Lisbon, Portugal, September 8-12, 2024
Exosomes Europe International Bioprocessing Summit
London, United Kingdom, June 6, 2024
PepTalk Revolutionizing the Future of Biotherapeutics
San Diego, CA, January 19, 2024
Waltham, MA, May 21-24, 2023
Can Recombinant Extracellular Vesicles be an Alternative Technology to Exosomes?
Digital Event, March 29, 2023
Targeting Specific Cells with Recombinant Vesicles
Targeted Intracellular Delivery Summit 2023
Boston, March 7-9, 2023
Transformational Vaccines and Therapeutics with Recombinant Extracellular Vesicles
6th Annual Cell & Gene Therapy Innovation Leaders Summit 2023
Berlin, February 15, 2023
Boston, October 3, 2022
Placing Patients at the Center - Panel Discussion
Longwood Healthcare Leaders Fall Conference
Boston, September 21, 2022
Therapeutic Delivery with Recombinant Nano-Vesicles
Vector Development for Cell and Gene Therapy Summit
Boston, August 25, 2022
Accelerating Outer Membrane Vesicle Vaccines Towards the Clinic
Drug Target Review Summit - Development of Next-Generation Vaccines Summit
Online Summit, June 9, 2022
Designing Potent Immunotherapies and Vaccines with the Power of ROMV's (recombinant outer membrane vesicles)
Applications of Exosomes: Meet the Exosome, the Rising Star in Drug Delivery
Digital Event, March 30, 2022
LOWELL, Mass., Sept. 11, 2024 Versatope Therapeutics Incorporated announced today their new Chief Medical Officer, Dr. M.P. Anza Mammen, MD and the addition of their Chairman of the Scientific Advisory Board, Dr. Robert B. Belshe.
Advancing Vaccines with Extracellular Vesicles
September 27, 2022 Dr. Christopher Locher, Versatope Therapeutics, explains why bacterial extracellular vesicles are ideally suited for recombinant vaccines because target antigens can be expressed as fusion proteins and targeted to the lumen, membrane or surface of the vesicles.
LOWELL, Mass., Oct. 14, 2021 Versatope announced today that Dr. Drew Weissman, a leading mRNA vaccine expert, joined their Scientific Advisory Board. Separately, Dr. James Kuo and Jeremy Gowler joined the company's Board of Directors to diversify their pipeline and expand their business development activities.
Versatope announced that two new Board of Directors, Dr. Salim Yazji and Ms. Brenda McCabe joined the company to support the company’s strategy and management.
Versatope Therapeutics received the first prize at the 11th Massachusetts Life Science Innovators (MALSI) conference
Versatope delivers drugs and vaccines from genetically engineered probiotics. Article from the Lowell Sun newspaper.
The 2018 200K M2D2 competition winners were announced on April 10th at Mintz Levin in Boston. Versatope took the second place prize. Congratulations to the team that worked hard to get us there.
Advancing drug delivery: Convergence and Medical Devices/Drugs Symposium
Versatope was selected as a resident company by Johnson & Johnson Innovation, JLABS at the M2D2 incubator in Lowell, Massachusetts
Versatope selected as a finalist in the 200K M2D2 Challenge
Versatope Therapeutics celebrated the launch of its new laboratory space at the Massachusetts Medical Device Development Center (M2D2) incubator at the University of Massachusetts Lowell.
Versatope won the the 1st Annual Massachusetts Jump Start Grant Challenge sponsored by PharmaDirections, in cooperation with MassBio.
This MassCONNECT® class includes entrepreneurs working to fight diabetes, discover drugs by screening in living animal models, revolutionize intravascular therapeutic embolization and deliver immunity with designer recombinant nanoparticles
128 high-impact companies to access global network of support and resources in Boston
A seasonal flu shot is a bit like a local weather forecast: Based on the conditions elsewhere and the direction of the prevailing wind, a meteorologist can give the public a pretty good idea of what to expect in the near future. Experts who track influenza’s intercontinental travels basically do the same thing.
For 30 years, conjugate vaccines have proven effective in reducing the incidence of disease caused by bacterial pathogens, including Haemophilus influenzae type b (Hib), a form of bacterial meningitis that kills thousands of infants annually in the underdeveloped world.
Mention E. coli and what pops into most people’s heads are bacteria, tainted food, a rush to the hospital – basically, fear. “E. coli gets a bad rap – and rightfully so,” said Matthew DeLisa, the William L. Lewis Professor of Engineering.
All Rights Reserved |
Versatope Therapeutics
110 Canal St, Fl 4
Lowell, MA 01852